AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 272 min read$CYTK

Blum Robert I sold $607K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $80.87 ($0.61M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Jul 27, 2026, 8:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The disclosure provides a concrete, same-day datapoint on insider selling activity, but it does not introduce new company fundamentals.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the planned nature of the sale limits fundamental implications.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total CEO holdings or prior sale cadence.

Relevance 4/10Novelty 5/10Timing: filed 2026-07-27, after-hours SEC Form 4 disclosure

Background

This is an SEC Form 4 insider transaction for Cytokinetics, reported by the company’s President and CEO.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOKINETICS CEO Robert Blum filed a Form 4 selling 7,500 shares at $80.87 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst beyond typical insider-sale interpretation.

Evidence & confidence

The filing is primary-source and time-stamped, but it is a planned 10b5-1 sale and the article provides no new operational, financial, or regulatory developments.

Market effects

Sector

No direct sector read-across; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    US-listed company whose CEO insider sale is disclosed on Form 4.

  • insider
    Blum Robert I

    President and CEO reporting an open-market sale of 7,500 shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.

pharmaphorum.com4 min
JUL 24
$CYTKMed

What Makes Cytokinetics' MYQORZO Launch a Game Changer

Cytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.

kavout.com6 min
JUN 1
$CYTKMedAI 8/10

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics (Nasdaq: CYTK) said MYQORZO® (aficamten) has launched commercially in Germany, the first European availability, for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA II–III). The company cited EU approval in February 2026 based on SEQUOIA-HCM Phase 3 results, including a 1.76 mL/kg/min pVO2 improvement vs 0.0 with placebo over 24 weeks.

manilatimes.net4 min